Published in Cancer on December 15, 1997
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging (2008) 3.24
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging (2004) 2.58
A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. IEEE Trans Med Imaging (2009) 2.22
What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys (2011) 1.91
Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging (2008) 1.76
PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging (2010) 1.60
Initial clinical results for breath-hold CT-based processing of respiratory-gated PET acquisitions. Eur J Nucl Med Mol Imaging (2008) 1.59
18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med (2009) 1.53
PET functional volume delineation: a robustness and repeatability study. Eur J Nucl Med Mol Imaging (2011) 1.41
Positron Emission Tomography (PET) in Oncology. Cancers (Basel) (2014) 1.41
Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging (2010) 1.40
MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy. J Nucl Med (2012) 1.40
Fuzzy hidden Markov chains segmentation for volume determination and quantitation in PET. Phys Med Biol (2007) 1.33
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2007) 1.33
Robustness of intratumour ¹⁸F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. Eur J Nucl Med Mol Imaging (2013) 1.33
A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging (2008) 1.32
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med (2011) 1.18
Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging (2008) 1.17
Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging (2012) 1.16
Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia (2001) 1.11
Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging (2009) 1.11
Developing imaging strategies for castration resistant prostate cancer. Acta Oncol (2011) 1.10
Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. Eur Radiol (2012) 1.09
Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging (2009) 1.03
Joint segmentation of anatomical and functional images: applications in quantification of lesions from PET, PET-CT, MRI-PET, and MRI-PET-CT images. Med Image Anal (2013) 1.02
FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol (2008) 1.02
Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med (2006) 1.00
Predicting future morphological changes of lesions from radiotracer uptake in 18F-FDG-PET images. PLoS One (2013) 0.99
A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One (2011) 0.98
Local motion correction for lung tumours in PET/CT--first results. Eur J Nucl Med Mol Imaging (2008) 0.98
Monitoring radiographic brain tumor progression. Toxins (Basel) (2011) 0.98
A graph-theoretic approach for segmentation of PET images. Conf Proc IEEE Eng Med Biol Soc (2011) 0.95
A review on segmentation of positron emission tomography images. Comput Biol Med (2014) 0.94
Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging (2013) 0.91
PET-based delineation of tumour volumes in lung cancer: comparison with pathological findings. Eur J Nucl Med Mol Imaging (2013) 0.90
18F-FDG PET/CT-based gross tumor volume definition for radiotherapy in head and neck cancer: a correlation study between suitable uptake value threshold and tumor parameters. Radiat Oncol (2010) 0.90
Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2006) 0.90
Targeted molecular imaging in oncology: focus on radiation therapy. Semin Radiat Oncol (2008) 0.89
Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging (2014) 0.89
Recommendations of the Spanish Societies of Radiation Oncology (SEOR), Nuclear Medicine & Molecular Imaging (SEMNiM), and Medical Physics (SEFM) on (18)F-FDG PET-CT for radiotherapy treatment planning. Rep Pract Oncol Radiother (2012) 0.89
Optimal co-segmentation of tumor in PET-CT images with context information. IEEE Trans Med Imaging (2013) 0.89
HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2014) 0.89
Comparative evaluation of CT-based and respiratory-gated PET/CT-based planning target volume (PTV) in the definition of radiation treatment planning in lung cancer: preliminary results. Eur J Nucl Med Mol Imaging (2013) 0.89
The impact of 3D volume of interest definition on accuracy and precision of activity estimation in quantitative SPECT and planar processing methods. Phys Med Biol (2010) 0.88
Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma. PLoS One (2015) 0.87
From anatomical to biological target volumes: the role of PET in radiation treatment planning. Cancer Imaging (2006) 0.87
A partial volume effect correction tailored for 18F-FDG-PET oncological studies. Biomed Res Int (2013) 0.86
(18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys (2008) 0.86
The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging (2013) 0.85
Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation. Int J Radiat Oncol Biol Phys (2008) 0.85
Current concepts on imaging in radiotherapy. Eur J Nucl Med Mol Imaging (2007) 0.85
Respiratory gated [18F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases. Strahlenther Onkol (2012) 0.85
Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol (2015) 0.84
CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients. BMC Cancer (2014) 0.83
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2). Eur J Nucl Med Mol Imaging (2014) 0.82
Assessing and accounting for the impact of respiratory motion on FDG uptake and viable volume for liver lesions in free-breathing PET using respiration-suspended PET images as reference. Med Phys (2014) 0.81
Variability of Gross Tumor Volume in Nasopharyngeal Carcinoma Using 11C-Choline and 18F-FDG PET/CT. PLoS One (2015) 0.81
A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. J Neurosurg (2014) 0.80
Size-dependent thresholding as an optimal method for tumor volume delineation on positron emission tomography-computed tomography: A Phantom study. Indian J Nucl Med (2011) 0.80
Automatic Segmentation of Lung Carcinoma Using 3D Texture Features in 18-FDG PET/CT. Int J Mol Imaging (2013) 0.80
Combining multiple FDG-PET radiotherapy target segmentation methods to reduce the effect of variable performance of individual segmentation methods. Med Phys (2013) 0.79
The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. Gynecol Oncol (2013) 0.79
Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging (2007) 0.78
Use of FDG-PET in Radiation Treatment Planning for Thoracic Cancers. Int J Mol Imaging (2012) 0.78
Exploring the use of shape and texture descriptors of positron emission tomography tracer distribution in imaging studies of neurodegenerative disease. J Cereb Blood Flow Metab (2015) 0.78
Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer. Eur J Nucl Med Mol Imaging (2014) 0.78
The utility of positron emission tomography in the treatment planning of image-guided radiotherapy for non-small cell lung cancer. Front Oncol (2014) 0.78
18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response. J Nucl Med (2016) 0.78
Variability of ¹⁸F-FDG-positive lung lesion volume by thresholding. Eur Radiol (2012) 0.77
Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging (2012) 0.77
Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer. Br J Radiol (2016) 0.77
Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. Eur J Nucl Med Mol Imaging (2011) 0.77
Impact of CT attenuation correction method on quantitative respiratory-correlated (4D) PET/CT imaging. Med Phys (2015) 0.77
Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer. Clin Lung Cancer (2015) 0.77
Determination of an optimal standardized uptake value of fluorodeoxyglucose for positron emission tomography imaging to assess pathological volumes of cervical cancer: a prospective study. PLoS One (2013) 0.77
Segmentation of PET images for computer-aided functional quantification of tuberculosis in small animal models. IEEE Trans Biomed Eng (2013) 0.76
(18)F-FDG avid volumes on pre-radiotherapy FDG PET as boost target delineation in non-small cell lung cancer. Int J Clin Exp Med (2015) 0.76
Optimal definition of biological tumor volume using positron emission tomography in an animal model. EJNMMI Res (2015) 0.76
Motion freeze for respiration motion correction in PET/CT: a preliminary investigation with lung cancer patient data. Biomed Res Int (2014) 0.75
Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. Br J Cancer (2015) 0.75
Hybrid positron emission tomography segmentation of heterogeneous lung tumors using 3D Slicer: improved GrowCut algorithm with threshold initialization. J Med Imaging (Bellingham) (2017) 0.75
A comparison of amplitude-based and phase-based positron emission tomography gating algorithms for segmentation of internal target volumes of tumors subject to respiratory motion. Int J Radiat Oncol Biol Phys (2013) 0.75
The use of positron emission tomography/computed tomography imaging in radiation therapy: a phantom study for setting internal target volume of biological target volume. Radiat Oncol (2015) 0.75
Influence of rigid coregistration of PET and CT data on metabolic volumetry: a user's perspective. EJNMMI Res (2013) 0.75
Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. Eur Radiol (2014) 0.75
Multi-observation PET image analysis for patient follow-up quantitation and therapy assessment. Phys Med Biol (2011) 0.75
PET image segmentation using a Gaussian mixture model and Markov random fields. EJNMMI Phys (2015) 0.75
Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer. Br J Radiol (2017) 0.75
Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation. Eur J Nucl Med Mol Imaging (2015) 0.75
Adaptive region-growing with maximum curvature strategy for tumor segmentation in (18)F-FDG PET. Phys Med Biol (2017) 0.75
Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. Eur J Nucl Med Mol Imaging (2016) 0.75
Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med (1975) 5.30
Single-particle electron cryo-microscopy: towards atomic resolution. Q Rev Biophys (2000) 4.86
Automated detection of Haemophilus influenzae. Appl Microbiol (1973) 3.16
Transplacental haemorrhage. Br J Haematol (1966) 3.02
Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res (1998) 2.55
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res (1998) 2.43
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res (1996) 2.22
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst (1991) 2.19
Imaging transgene expression with radionuclide imaging technologies. Neoplasia (2000) 2.03
Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol (1999) 2.02
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol (2002) 1.96
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab (1999) 1.90
Immunological responses in pregnancy and survival of fetal homograft. Br Med J (1972) 1.86
Dose of anti-D gamma-globulin in prevention of Rh-haemolytic disease of the newborn. Br Med J (1966) 1.79
Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions. J Cereb Blood Flow Metab (2000) 1.77
Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med (2000) 1.74
Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys (2004) 1.74
Quantitative imaging of iodine-124 with PET. J Nucl Med (1996) 1.69
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg (1999) 1.67
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid (2000) 1.59
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab (2000) 1.59
Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab (2000) 1.56
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol (1998) 1.56
Depression of cellular immunity in pregnancy due to a serum factor. Br Med J (1973) 1.54
Phase and amplitude binning for 4D-CT imaging. Phys Med Biol (2007) 1.52
Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. J Nucl Med (1966) 1.49
FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med (2001) 1.49
Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys (2002) 1.48
"Food allergy": Fact or Fiction? Lancet (1978) 1.44
Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol (2001) 1.44
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Frequency-distribution curve of uric acid in the general population. Lancet (1966) 1.42
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol (1988) 1.41
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol (1994) 1.41
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
Triumph over mischance: a role for nuclear medicine in gene therapy. J Nucl Med (1997) 1.41
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
A much misunderstood caduceus and the case for an aesculapion. Lancet (1999) 1.40
Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology (2001) 1.40
Oncologist's role critical to clinical trial enrollment. J Natl Cancer Inst (2000) 1.38
Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia (2002) 1.36
Quantitative bone metastases analysis based on image segmentation. J Nucl Med (1997) 1.36
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol (1993) 1.35
Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys (2004) 1.35
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol (1998) 1.35
On the behavior of a capillary surface in a wedge. Proc Natl Acad Sci U S A (1969) 1.34
Dimensions of the normal adult spleen scan and prediction of spleen weight. J Nucl Med (1971) 1.33
Highest isotope count does not predict sentinel node positivity in all breast cancer patients. Ann Surg Oncol (2001) 1.32
Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum (2000) 1.32
Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med (1986) 1.27
Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg (1985) 1.27
Serum antibodies reactive with Saccharomyces cerevisiae in inflammatory bowel disease: is IgA antibody a marker for Crohn's disease? Int Arch Allergy Appl Immunol (1990) 1.26
Midazolam changes cerebral blood flow in discrete brain regions: an H2(15)O positron emission tomography study. Anesthesiology (1997) 1.25
Surveys identify barriers to participation in clinical trials. J Natl Cancer Inst (2000) 1.25
A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia (1999) 1.25
Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res (1999) 1.24
Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med (1983) 1.24
Effects of obstetrician gender on communication and patient satisfaction. Obstet Gynecol (1999) 1.23
Use-dependent structural events in recovery of function. Adv Neurol (1997) 1.23
Plasma exchange in myasthenia gravis. Lancet (1977) 1.23
Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A (2001) 1.22
Spontaneous abortion and fetal abnormality in subsequent pregnancy. Br Med J (1978) 1.22
Hydrocarbon exposure and glomerulonephritis. Clin Nephrol (1980) 1.22
Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab (2013) 1.21
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1996) 1.21
The radionuclide ejection fraction: a comparison of three radionuclide techniques with contrast angiography. J Nucl Med (1977) 1.18
Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid (2001) 1.17
The small GTPase Rab4A interacts with the central region of cytoplasmic dynein light intermediate chain-1. Biochem Biophys Res Commun (2001) 1.17
A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg (2001) 1.17
The pharmacology of monoclonal antibodies. Ann N Y Acad Sci (1987) 1.15
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer (2008) 1.15
Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl Med (1985) 1.14
Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med (1996) 1.13
ABO blood group distribution in serum hepatitis. Br Med J (1969) 1.13